AVTX

Avalo Therapeutics Stock Analysis

AI Rating

Low
  • Quality4/10
  • Growth↑ 5/10
  • Value↓ 0/10
Avalo Therapeutics sales and earnings growth
AVTX Growth
Neutral
  • Revenue Y/Y↓ -76.59%
  • EPS Y/Y↑ 27.98%
  • FCF Y/Y↓ -42.08%
Avalo Therapeutics gross and profit margin trends
AVTX Profitability
Low
  • Gross margin ↑ 54.70%
  • EPS margin↓ -52019.80%
  • ROIC 5Y↓ 343.17%
Avalo Therapeutics net debt vs free cash flow
AVTX Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -83.0

Avalo Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗